Nothing Special   »   [go: up one dir, main page]

WO2024054408A1 - Dosage supplémentaire et administration d'anticorps anti-c5 pour le traitement de la microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma) - Google Patents

Dosage supplémentaire et administration d'anticorps anti-c5 pour le traitement de la microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma) Download PDF

Info

Publication number
WO2024054408A1
WO2024054408A1 PCT/US2023/031836 US2023031836W WO2024054408A1 WO 2024054408 A1 WO2024054408 A1 WO 2024054408A1 US 2023031836 W US2023031836 W US 2023031836W WO 2024054408 A1 WO2024054408 A1 WO 2024054408A1
Authority
WO
WIPO (PCT)
Prior art keywords
dose
patient weighing
patient
day
antibody
Prior art date
Application number
PCT/US2023/031836
Other languages
English (en)
Inventor
Stephan ORTIZ
Jonathan MONTELEONE
Xiaofeng Wang Rears
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of WO2024054408A1 publication Critical patent/WO2024054408A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • Thrombotic microangiopathy is a post-transplant complication of hematopoietic stem cell transplant (HSCT) that may affect 10% to 35% of HSCT recipients (Dvorak et al., Front Pediatr. 2019;7: 133); Jodele et al., Blood Rev. 2015;29(3): 191-204; Seaby et al., Pediatr Nephrol. 2018;33(9): 1489-1500). It presents via endothelial injury and affects the kidney and other organs. It is estimated that 30% of patients with HSCT TMA will present with severe disease (Rosenthal et al., J. BloodMed.
  • HSCT-TMA typically occurs early post allogeneic HSCT, with a median diagnosis at 35 to 47 days post-HSCT, and 88% to 92% occurring before Day +100.
  • cases have been reported up to 2 years post-HSCT.
  • Autologous recipients may develop HSCT TMA even earlier, with a median of 18 days post-HSCT (Dvorak et al., Front Pediatr. 2019;7: 133).
  • Endothelial injury is fundamental to the pathogenesis of HSCT-TMA, with dysregulated complement activation likely to be a consequence of the endothelial damage.
  • Risk factors associated with HSCT-TMA development that also initiate endothelial damage include calcineurin inhibitors (CNIs), infections, and conditioning regimens (high dose chemotherapy or total body irradiation) (Khosla, et al., Bone Marrow Transplant. 2018;53(2): 129-137; Masias, et al., Blood. 2017;129(21):2857-2863).
  • CNIs calcineurin inhibitors
  • infections infections
  • conditioning regimens high dose chemotherapy or total body irradiation
  • HSCT-TMA Currently, there are no approved therapies for the treatment of HSCT-TMA.
  • Primary intervention for HSCT-TMA involves withdrawal of the offending agent (e.g, CNIs) and/or treatment of any trigger conditions (e.g., treatment for infections) (Dvorak, et al., Front Pediatr. 2019;7: 133); Seaby el al., Pediatr. Nephrol. 2018;33(9): 1489-1500).
  • the offending agent and/or treatment of any associated trigger condition does not reverse the HSCT-TMA. Accordingly, it is an object of the present disclosure to provide improved methods for treating patients with HSCT-TMA.
  • HSCT-TMA patients treated with ravulizumab according to a particular clinical dosage regimen e.g, at particular loading and maintenance dose amounts and according to a specific dosing schedule
  • who received one or more transfusions e.g, platelet or red blood cell (RBC) transfusions
  • RBC red blood cell
  • a supplemental dosing simulation model the inventors have identified that delivery of a supplemental dose of ravulizumab to attain a mean (standard deviation) minimum and maximum plasma concentration of ravulizumab during a dosing interval that is between 474 (200) pg/mL and 1350 (430) pg/mL, respectively, provided a more effective treatment to HSCT-TMA patients who have undergone transfusion, e.g., RBC transfusion, during treatment.
  • transfusion e.g., RBC transfusion
  • HSCT patients with body weight >30 kg who received any (e.g, one, two, three, or more) RBC transfusions in the 4 weeks following a maintenance dose were administered a supplemental dose of ravulizumab 4 weeks after that maintenance dose.
  • the supplemental ravulizumab dose regimen achieved immediate, complete, and sustained terminal complement inhibition.
  • the supplemental dosing scheme was also applied to effectively treat HSCT-TMA patients in the lower body weight (e.g, ⁇ 30 kg) and particularly ultra-low body weight (e.g, ⁇ 20 kg, and particularly ⁇ 10 kg) cohorts.
  • HSCT patients with body weight ⁇ 30 kg who received any (e.g, one, two, three, or more) RBC transfusions within a specified timeframe e.g, 2 w eeks for patients who are ⁇ 20 kg and 4 weeks for patients who are >20 kg (e.g, 20 kg ⁇ 30 kg; 30 kg ⁇ 40 kg; 40 kg ⁇ 60 kg; 60 kg ⁇ 100 kg; or > 100 kg)
  • a maintenance dose were administered a supplemental dose of ravulizumab at the specified timeframe after that maintenance dose.
  • the supplemental ravulizumab dose regimen achieved immediate, complete, and sustained terminal complement inhibition.
  • HSCT-TMA in a particular patient sub-population
  • a transfusion e.g., platelet or RBC transfusion
  • a maintenance dose comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) according to a particular clinical dosage regimen (e.g, at particular loading, maintenance, and one or more supplemental dose amounts, and according to a specific schedule).
  • Also provided herein are methods for treating HSCT-TMA in a particular patient sub-population e.g., HSCT-TMA patients with body weight ⁇ 30 kg who received a transfusion (e.g, platelet or RBC transfusion) in the 2 weeks ( ⁇ 20 kg) or 4 weeks (>20 kg to 30 kg) following a maintenance dose), comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) according to a particular clinical dosage regimen (e.g, at particular loading, maintenance, and one or more supplemental dose amounts, and according to a specific schedule).
  • a transfusion e.g, platelet or RBC transfusion
  • An exemplary anti-C5 antibody is ravulizumab (ULTOMIRIS®) comprising the heavy and light chains having the sequences shown in SEQ ID NOs: 14 and 11, respectively, or antigen binding fragments and variants thereof.
  • the antibody comprises the heavy and light chain complementarity determining regions (CDRs) or variable regions (VRs) of ravulizumab.
  • the antibody comprises the CDR1, CDR2 and CDR3 domains of the heavy chain variable (VH) region of ravulizumab having the sequence shown in SEQ ID NO: 12, and the CDR1, CDR2 and CDR3 domains of the light chain variable (VL) region of ravulizumab having the sequence shown in SEQ ID NO: 8.
  • the antibody comprises CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively.
  • the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO: 8, respectively.
  • the antibody comprises a heavy chain constant region as set forth in SEQ ID NO: 13.
  • the antibody comprises a variant human Fc constant region that binds to human neonatal Fc receptor (FcRn), wherein the variant human Fc CH3 constant region comprises Met429Leu and Asn435Ser substitutions at residues corresponding to methionine 428 and asparagine 434 of a native human IgG Fc constant region, each according to the EU numbering convention.
  • FcRn human neonatal Fc receptor
  • the antibody comprises CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively and a variant human Fc constant region that binds to human neonatal Fc receptor (FcRn), wherein the variant human Fc CH3 constant region comprises Met429Leu and Asn435Ser substitutions at residues corresponding to methionine 428 and asparagine 434 of a native human IgG Fc constant region, each according to the EU numbering convention.
  • FcRn human neonatal Fc receptor
  • the anti-C5 antibody comprises the heavy and light chain CDRs or variable regions of the BNJ421 antibody (described in WO2015134894 and US Patent No. 9,079,949). In another embodiment, the anti-C5 antibody comprises the heavy and light chain CDRs or variable regions of the 7086 antibody (see US Patent Nos. 8,241,628 and 8,883,158). In another embodiment, the anti-C5 antibody comprises the heavy and light chain CDRs or variable regions of the 8110 antibody (see US Patent Nos. 8,241,628 and 8,883,158). In another embodiment, the anti-C5 antibody comprises the heavy and light chain CDRs or variable regions of the 305LO5 antibody (see US Patent No. 9,765,135). In another embodiment, the anti-C5 antibody comprises the heavy and light chain CDRs or variable regions of the SKY59 antibody. In another embodiment, the anti-C5 antibody comprises the heavy and light chain CDRs or variable regions of the REGN3918 antibody.
  • the anti-C5 antibody is a biosimilar of eculizumab (SOLIRIS®).
  • the anti-C5 antibody is, for example, ABP 959 antibody (manufactured by Amgen Inc., USA), ELIZARIA® (manufactured by Generium JNC, Russia), SB 12 (manufactured by Samsung Bioepis, Incheon, South Korea), ISU305 (eculizumab biosimilar from ISU Abxis, South Korea), ABLYZE® (eculizumab biosimilar from CinnaGen, Iran), BCD 148 (eculizumab biosimilar from Biocad Medical, Quebec, Canada), tesidolumab (manufactured by Novartis), Crovalimab (manufactured by Roche), CAN106 (manufactured by CanBridge Pharmaceuticals, China) or Pozelimab (manufactured by Regeneron).
  • ABP 959 antibody manufactured by Amgen Inc., USA
  • the antibody competes for binding with, and/or binds to the same epitope on C5 as any of the above-mentioned antibodies.
  • the antibody has at least about 90% variable region amino acid sequence identity to any of the above-mentioned antibodies (e.g, at least about 90%, 95% or 99% variable region identity with SEQ ID NO: 12 or SEQ ID NO: 8)
  • the antibody binds to human C5 at pH 7.4 and 25°C with an affinity dissociation constant (KD) that is in the range 0.1 nM ⁇ KD ⁇ 1 nM. In another embodiment, the antibody binds to human C5 at pH 7.4 and 25°C with an affinity dissociation constant (KD) of about 0.5 nM. In another embodiment, the antibody binds to human C5 at pH 6.0 and 25 °C with a KD > 10 nM. In another embodiment, the antibody binds to human C5 at pH 6.0 and 25°C with a KD of about 22 nM.
  • KD affinity dissociation constant
  • the [(KD of the antibody or antigen-binding fragment thereof for human C5 at pH 6.0 and at 25°C)/(KD of the antibody or antigen-binding fragment thereof for human C5 at pH 7.4 and at 25°C)] of the antibody is greater than 25.
  • dosage regimens described herein provide an optimal desired response (e.g., an effective treatment).
  • effective treatment comprises attaining an immediate, complete, and sustained terminal complement inhibition in the patient with HSCT-TMA.
  • methods for treating HSCT-TMA in a patient who has undergone transfusion comprising phased dosing, followed by maintenance dosing, and supplemental dosing.
  • the anti-C5 antibody, or antigen binding fragment thereof is administered a loading dose once on Day 1 (e.g., of the administration cycle), at a loading dose once on Day 5 (e.g., of the administration cycle), at a loading dose once on Day 10 (e.g., of the administration cycle) and a maintenance dose every eight weeks thereafter starting at Day 15.
  • the maintenance dose of the anti-C5 antibody, or antigen binding fragment thereof is administered every eight weeks after treatment (e.g., an administration cycle) for an extension period up to two years.
  • the anti-C5 antibody, or antigen binding fragment thereof is administered at a loading dose once on Day 1 (e.g., of the administration cycle), at a loading dose once on Day 5 (e.g., of the administration cycle), at a loading dose once on Day 10 (e.g., of the administration cycle), a maintenance dose every eight weeks thereafter starting at Day 15, along with a supplemental dose.
  • a supplemental dose is administered to a patient who receives a red blood cell (RBC) transfusion within four w eeks of a maintenance dose, wherein the supplemental dose is administered four weeks after that maintenance dose.
  • RBC red blood cell
  • a supplemental dose is administered to a patient weighing > 30 kg who receives a RBC transfusion within four w eeks of a maintenance dose, wherein the supplemental dose is administered four weeks after that maintenance dose at a dose of: 2700 mg to a patient weighing > 30 to ⁇ 40 kg, 3000 mg to a patient weighing > 40 to ⁇ 60 kg, 3300 mg to a patient weighing > 60 to ⁇ 100 kg, or 3600 mg to a patient weighing > 100 kg.
  • a method of treating a human patient with HSCT-TMA preferably an RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody or antigen binding fragment thereof, is administered:
  • a method of treating a human patient with HSCT-TMA preferably an RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively and a variant human Fc constant region that binds to human neonatal Fc receptor (FcRn), wherein the variant human Fc CH3 constant region comprises Met429Leu and Asn435Ser substitutions at residues corresponding to methionine 428 and asparagine 434 of a native human IgG Fc constant region, each according to the EU numbering convention, wherein the anti-C5 antibody is administered:
  • a method of treating a human patient with HSCT-TMA preferably an RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of ravulizumab, wherein ravulizumab is administered:
  • the treatment results in a reduction in LDH levels to within normal levels or to within 50% below what is considered the ULN level (e.g., within 105-333 IU/L (international units per liter), a serum trough concentration of the anti-C5 antibody, or antigen binding fragment thereof, of at least 175 pg/mL or greater, and/or a free C5 concentration of 0.5 pg/mL or less (e.g., 0.4 pg/mL, 0.3 pg/rnL, 0.2 pg/mL, or 0.1 pg/mL or less).
  • a method of treating a human patient with HSCT-TMA preferably an RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing 5 to ⁇ 10 kg:
  • an anti-C5 antibody, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C
  • a supplemental dose of 300 mg to the patient who receives RBC transfusion within a specified timeframe of a maintenance dose, wherein the supplemental dose is administered at the specified timeframe following the maintenance dose, wherein the specified timeframe is two weeks.
  • a method of treating a human patient with HSCT-TMA preferably an RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing 5 to ⁇ 10 kg:
  • an anti-C5 antibody, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C
  • a supplemental dose of 400 mg to the patient who receives RBC transfusion within a specified timeframe of a maintenance dose, wherein the supplemental dose is administered at the specified timeframe following the maintenance dose, wherein the specified timeframe is two weeks.
  • a method of treating a human patient with HSCT-TMA preferably an RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing 10 to ⁇ 20 kg:
  • an anti-C5 antibody, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C
  • a supplemental dose of 600 mg to the patient who receives RBC transfusion within a specified timeframe of a maintenance dose, wherein the supplemental dose is administered at the specified timeframe following the maintenance dose, wherein the specified timeframe is two weeks.
  • a method of treating a human patient with HSCT-TMA preferably an RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing 10 to ⁇ 20 kg:
  • a supplemental dose of 800 mg to the patient who receives RBC transfusion within a specified timeframe of a maintenance dose, wherein the supplemental dose is administered at the specified timeframe following the maintenance dose, wherein the specified timeframe is two weeks.
  • a method of treating a human patient with HSCT-TMA preferably to RBC-transfused HSCT-TMA patient, the method comprising administering to the patient an effective amount of an anti-C5 anti body, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing 20 to ⁇ 30 kg:
  • an anti-C5 anti body, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5
  • a supplemental dose of 2100 mg to the patient who receives RBC transfusion within a specified timeframe of a maintenance dose, wherein the supplemental dose is administered at the specified timeframe following the maintenance dose, wherein the specified timeframe is four weeks.
  • the supplemental dose is administered if warranted per a clinical algorithm as set forth in FIG. 3. In some embodiments, the supplemental dose is administered if warranted per a clinical algorithm as set forth in Table 7.
  • a method of treating a human patient with HSCT-TMA preferably RBC-transfused HSCT-TMA patent, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing > 30 to
  • a method of treating a human patient with HSCT-TMA preferably RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing > 30 to
  • a method of treating a human patient with HSCT-TMA preferably RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing > 40 to
  • a method of treating a human patient with HSCT-TMA, preferably RBC transfused HSCT-TMA patient comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing > 40 to
  • a method of treating a human patient with HSCT-TMA preferably an RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing > 60 to
  • a method of treating a human patient with HSCT-TMA preferably an RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing > 60 to
  • a method of treating a human patient with HSCT-TMA preferably an RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing > 100 kg:
  • an anti-C5 antibody, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody or anti
  • a method of treating a human patient with HSCT-TMA preferably an RBC-transfused HSCT-TMA patient, is provided, the method comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing > 100 kg:
  • an anti-C5 antibody, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody or anti
  • the patient receives a post-transfusion supplemental dose of the anti-C5 antibody (e.g., ravulizumab) once only at the mid-way point between 2 maintenance doses.
  • a post-transfusion supplemental dose of the anti-C5 antibody e.g., ravulizumab
  • the supplemental dose of the anti- C5 antibody is administered after week 2, e.g., 14 days after the maintenance dose.
  • the patient receives a post-transfusion supplemental dose of the anti-C5 antibody (e.g., ravulizumab) once only at the mid-way point between 2 maintenance doses. Since the maintenance doses are administered every eight weeks (Q8W), the supplemental dose of the anti-C5 antibody (e.g., ravulizumab) is administered after week 4, e.g., 28 days after the maintenance dose. In such embodiments, if the patient does not undergo any transfusions during the second maintenance dosing period, then no supplemental dose is needed during this maintenance dosing cycle.
  • a post-transfusion supplemental dose of the anti-C5 antibody e.g., ravulizumab
  • the supplemental dosing regimen is continued until no transfusions are administered, in the 2- week period for participants with body weight ⁇ 20 kg or in the 4-week period for participants with body weight > 20 kg, following a given maintenance dose.
  • a post-transfusion supplemental dose of the anti-C5 antibody, or antigen binding fragment thereof, is administered to the HSCT-TMA patient once, e.g., only 2 weeks ( ⁇ 20 kg patients) or only 4 weeks (> 20 kg patients) after the last maintenance dose, if any amount of RBC transfusion is provided to the patient within the 2 weeks or 4 weeks after the last maintenance dose.
  • the anti-C5 antibody, or antigen binding fragment thereof is administered for one or more administration cycles.
  • the treatment e.g. , administration cycle
  • the treatment is at least 26 weeks, at least 52 weeks, at least 1.5 years, at least 2 years.
  • immediate, complete, and sustained terminal complement inhibition is achieved following administration of a supplement dose of the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab).
  • the methods of treatment disclosed herein further comprise administering best supportive care (BSC) measures.
  • BSC measures include, but are not limited to, transfusion support, corticosteroids, dialysis, and antihypertensive medications.
  • the patient has not previously been treated with eculizumab.
  • the patent has previously been treated with eculizumab.
  • the patient has previously been treated with eculizumab and Day 1 (e.g., of the administration cycle) is two weeks or more from the patient’s last dose of eculizumab.
  • the treatment regimens described are sufficient to maintain particular serum trough concentrations of the anti-C5 antibody or antigen binding fragment thereof.
  • the treatment regimen maintains a serum trough concentration of the anti-C5 antibody or antigen binding fragment thereof of 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 200, 205, 210, 215, 220, 225, 230, 240, 245, 250, 255, 260, 265, 270,
  • the treatment regimen maintains a serum trough concentration of the anti-C5 antibody or antigen binding fragment thereof of 100 pg/mL or greater, 150 pg/mL or greater, 200 pg/mL or greater, 250 pg/mL or greater, 300 pg/mL or greater, 350 pg/mL or greater, 400 pg/mL or greater, or 450 pg/mL or greater.
  • the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen binding fragment thereof of between 100 pg/mL and 700 pg/mL; preferably between 300 pg/mL and 600 pg/mL. In another embodiment, the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen binding fragment thereof of about 475 pg/mL.
  • the treatment regimen maintains a serum peak concentration of the anti-C5 antibody or antigen binding fragment thereof of less than about 1800, 1780, 1760, 1740, 1720, 1700, 1680, 1660, 1640, 1620, 1600, 1580, 1560, 1540, 1520, 1500, 1480, 1460, 1440, 1420, 1400, 1380, 1360, 1340, 1320, 1300, 1280, 1260, 1240, 1220, 1200, 1180, 1160, 1140, 1120, 1100, 1080, 1060, 1040, 1020, 1000, 980, 960, 940, 920, or 900 pg/mL, or less.
  • the treatment maintains a peak serum concentration of the anti-C5 antibody or antigen binding fragment thereof of between 900 pg/mL and 1800 pg/mL; preferably between 1050 pg/mL and 1550 pg/mL. In another embodiment, the treatment maintains a peak serum concentration of the anti-C5 antibody or antigen binding fragment thereof of about 1350 pg/mL.
  • the anti-C5 antibody is administered to the patient in an amount and with a frequency to maintain at least 50 pg, 55 pg, 60 pg, 65 pg, 70 pg, 75 pg, 80 pg, 85 pg, 90 pg, 95 pg, 100 pg, 105 pg, 1 10 pg, 115 pg, 120 pg, 125 pg, 130 pg, 135 pg, 140 pg, 145 pg, 150 pg, 155 pg, 160 pg, 165 pg,
  • the anti-C5 antibody e.g., ravulizumab
  • the anti-C5 antibody is administered to the patient in an amount and with a frequency to maintain a minimum and maximum plasma concentration ( ⁇ standard deviation) of the anti-C5 antibody (e.g., ravulizumab) during a dosing interval that is preferably between 474 ( ⁇ 200) pg/mL and 1350 ( ⁇ 430) pg/mL, respectively.
  • the anti-C5 antibody is administered to the patient in an amount and with a frequency to maintain a minimum free C5 concentration.
  • the anti-C5 antibody is administered to the patient in an amount and with a frequency to maintain a free C5 concentration of 0.5 pg/mL or less (e.g., 0.4 pg/mL, 0.3 pg/mL, 0.2 pg/mL, or 0.1 pg/mL or less).
  • the anti-C5 antibodies, or antigen binding fragments thereof can be administered to a patient by any suitable means.
  • the antibodies are formulated for intravenous administration.
  • the efficacy of the treatment methods provided herein can be assessed using any suitable means.
  • the treatment produces at least one therapeutic effect selected from the group consisting of: a reduction or cessation in microangiopathic hemolytic anemia, thrombocytopenia, endothelial injury, kidney damage, kidney failure, serositis, pulmonary hypertension, and multisystem organ failure compared to baseline.
  • the treatment results in (a) platelet count > 50,000/mm 3 without transfusion support during the prior 7 days, (b) LDH ⁇ 1.5 x ULN, and (c) absence of schistocytes (if there were schistocytes present at baseline).
  • the treatment results in (a) platelet count > 50,000/mm 3 without transfusion support during the prior 7 days, (b) LDH ⁇ 1.5 * ULN, (c) absence of schistocytes (if there were schistocytes present at baseline) and (d) at least 50% reduction of proteinuria from baseline.
  • proteinuria is as protein/creatinine ratio > 0.5 mg/mg.
  • the treatment results in a favorable hematological response.
  • the treatment results in normalization of LDH, resolution of need for red cell and platelet transfusions, and disappearance of schistocytes.
  • the treatment results in the patient’s ability to maintain hemoglobin > 8 g/dL without transfusion support. In another embodiment, the treatment results in hemoglobin > 8 g/dL without transfusion support.
  • the treatment results in a decrease in LDH, an increase in platelets, and/or an increase in hemoglobin compared to baseline.
  • the treatment results in normal levels of serum creatinine compared to baseline.
  • the treatment results in an improvement in TMA-associated organ dysfunction in the renal, cardiovascular, pulmonary, CNS, and/or GI systems compared to baseline.
  • the treatment results in terminal complement inhibition.
  • the treatment produces a reduction in adverse events.
  • the treatment produces a shift toward normal levels of biomarkers associated with vascular inflammation (e.g., shed tumor necrosis factor receptor 1 [TNF-R1]), endothelial damage and/or activation (e.g., thrombomodulin and shed vascular cell adhesion molecule 1 [VCAM-1]), renal injury' (e.g., Cystatin C), and/or complement proteins and complement activation pathway products.
  • the treatment produces a shift toward normal levels of thrombomodulin (TM) and/or syndecan-1 (SYND1).
  • the treatment produces a shift toward normal levels of complement factor Ba.
  • the treatment produces a change from baseline in quality of life as assessed via a Quality of Life Assessment (e.g., a Quality of Life Inventory (PedsQL) Scale or an EQ-5D-5L questionnaire).
  • a Quality of Life Assessment e.g., a Quality of Life Inventory (PedsQL) Scale or an EQ-5D-5L questionnaire.
  • the treatment results in a reduction of hemolysis as assessed by lactate dehydrogenase (LDH) levels compared to baseline.
  • LDH lactate dehydrogenase
  • patients treated according to the disclosed methods experience reductions in LDH levels to near nomial levels or to within 10%, or within 20% above what is considered the normal level (e.g., within 105-333 IU/L (international units per liter).
  • the patient’s LDH levels are normalized throughout maintenance period of treatment.
  • the treated patient’s LDH levels are normalized at least at least 95% of the time while on the maintenance period of treatment.
  • the treated patient’s LDH levels are normalized at least at least 90%, 85% or 80% of the time while on the maintenance period of treatment.
  • the patient's LDH levels are > 1.5 fold above the upper limit of normal (LDH > 1.5 x ULN) prior to initiating treatment.
  • patients treated according to the disclosed methods experience reductions in LDH levels to within normal levels or to within 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% or within 50% below what is considered the ULN level (e.g., within 105-333 IU/L (international units per liter).
  • the patient’s LDH levels are > 1.5 fold above the ULN (LDH > 1.5 x ULN) prior to initiating treatment.
  • patients treated according to the disclosed methods experience an LDH percent change compared to baseline of 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53% 54%, 55%, 56%, 57%, 58%, 59%, or 60%.
  • kits that include a pharmaceutical composition containing an anti-C5 antibody or antigen binding fragment thereof, such as ravulizumab, and a pharmaceutically acceptable carrier, in a therapeutically effective amount adapted for use in the methods described herein, e.g., for effective treatment of an HSCT-TMA patient who has undergone at least one transfusion, e.g., platelet or RBC transfusion.
  • a pharmaceutical composition containing an anti-C5 antibody or antigen binding fragment thereof, such as ravulizumab, and a pharmaceutically acceptable carrier, in a therapeutically effective amount adapted for use in the methods described herein, e.g., for effective treatment of an HSCT-TMA patient who has undergone at least one transfusion, e.g., platelet or RBC transfusion.
  • the kit comprises: (a) a dose of an anti-C5 antibody or antigen binding fragment thereof, comprising CDR1 , CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO: 12, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO: 8; and (b) instructions for using the anti-C5 antibody or antigen binding fragment thereof in the methods described herein.
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing 5 to ⁇ 10 kg:
  • a supplemental dose of 300 mg with instructions that the supplemental dose is administered to a patient who receives a red blood cell (RBC) transfusion within 2 weeks of a maintenance dose, wherein the supplemental dose is administered two weeks after the maintenance dose.
  • RBC red blood cell
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing 5 to ⁇ 10 kg:
  • a supplemental dose of 400 mg with instructions that the supplemental dose is administered to a patient who receives RBC transfusion within 2 weeks of a maintenance dose, wherein the supplemental dose is administered two weeks after the maintenance dose.
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing 10 to ⁇ 20 kg:
  • a supplemental dose of 600 mg with instructions that the supplemental dose is administered to a patient who receives RBC transfusion within 2 weeks of a maintenance dose, wherein the supplemental dose is administered two weeks after the maintenance dose.
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing 10 to ⁇ 20 kg:
  • kits comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing 20 to ⁇ 30 kg:
  • a supplemental dose of 2100 mg with instructions that the supplemental dose is administered to a patient who receives RBC transfusion within 4 weeks of a maintenance dose, wherein the supplemental dose is administered four weeks after the maintenance dose.
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing > 30 to ⁇ 40 kg:
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing > 40 to ⁇ 60 kg:
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing > 60 to ⁇ 100 kg:
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing > 100 kg:
  • an anti-C5 antibody, or antigen-binding fragment thereof for use in treatment of an HSCT-TMA patient who has undergone RBC transfusion during a first half of a maintenance phase of treatment is provided, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered:
  • anti-C5, antibody or antigen-binding fragment thereof e.g., ravulizumab (ULTOMIRIS®)
  • ULTOMIRIS® ravulizumab
  • FIG. 1 is a graph showing the ravulizumab pharmacokinetic (PK) profile for each patient. At Day 5 and Day 10, ravulizumab concentration was maintained above the 175 pg/mL threshold (dashed line).
  • FIG. 2 is a graph showing free C5 concentration-time profile for each patient (i.e., pharmacodynamic (PD) profile). All patients demonstrated free C5 concentrations below the 0.5 pg/mL threshold (dashed line).
  • FIG. 3 is a schematic depicting the clinical algorithm for assessing post-RBC supplemental dosing.
  • the term “subject” or “patient” is a human patient (e.g., a patient having hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT- TMA)).
  • HSCT- TMA hematopoietic stem cell transplant-associated thrombotic microangiopathy
  • the term “pediatric” patient is a human patient that has been classified by a physician or caretaker as belonging to a non-adult category and can include, e.g., newborn (both preterm and of term), infants, children, and adolescents. Typically, pediatric patients are patients under 18 years of age ( ⁇ 18 years of age).
  • adult patient is a human patient that has been classified by a physician or caretaker as such, e.g., one who is not a newborn, infant, child or adolescent, e.g., based on age, developmental status, physiological features, etc.
  • adult patients are patients who are 18 years of age or older (>18 years of age).
  • HSCT-TMA is a multifactorial disorder caused by systemic vascular endothelial injury that can be triggered by several mechanisms during the transplant process. It presents via endothelial injury and affects the kidney and other organs. It is estimated that 30% of patients with HSCT TMA will present with severe disease (Rosenthal et al., J. Blood Med. 2016;7: l 81 -186), and in these cases, patients with HSCT-TMA develop systemic vascular injury manifesting in kidney damage, serositis, pulmonary hypertension, and multisystem organ failure.
  • a TMA diagnosis is based on all of the following criteria occurring simultaneously: (a) de novo thrombocytopenia or platelet transfusion refractoriness, where: de novo thrombocytopenia is defined as new decline in platelet count to ⁇ 50,000/mm 3 and transfusion refractoriness is defined as failure of the platelet increment 10-60 minutes post transfusion to exceed the transfusion trigger, or a rise of less than 10 x 10 9 /L 20-24 hours posttransfusion after at least 2 platelet transfusions, (b) de novo anemia (defined as a new decline in hemoglobin to ⁇ 8 g/dL) or increase in transfusion requirements (defined as the need to administer more frequent transfusions in order to maintain hemoglobin > 8 g/dL), (c) either one of the following markers of hemolysis: LDH > 1.5 x ULN or presence of schistocytes > 2 high power field (HPF) in peripheral blood smear, (d) proteinuria on spot urina
  • the presence of proteinuria should be confirmed by a second measurement (with the 2 measurements at least 4 hours apart); (e) presence of hypertension defined as the presence of any one of the 3 conditions: a systolic pressure > 139 mm Hg or a diastolic pressure greater than 80 mm Hg on 2 consecutive measurements at least 1 hour apart.
  • effective treatment refers to treatment producing a beneficial effect, e.g., amelioration of at least one symptom of a disease or disorder.
  • a beneficial effect can take the form of an improvement over baseline, e.g., an improvement over a measurement or observation made prior to initiation of therapy according to the method.
  • Effective treatment may refer to alleviation of at least one symptom of HSCT-TMA (e.g, microangiopathic hemolytic anemia, thrombocytopenia, endothelial injury, kidney damage, kidney failure, serositis, pulmonary hypertension, and multisystem organ failure).
  • HSCT-TMA e.g, microangiopathic hemolytic anemia, thrombocytopenia, endothelial injury, kidney damage, kidney failure, serositis, pulmonary hypertension, and multisystem organ failure.
  • an “effective amount” refers to an amount of an agent that provides the desired biological, therapeutic and/or prophylactic result. That result can be reduction, amelioration, palliation, lessening, delaying and/or alleviation of one or more of the signs, symptoms or causes of a disease, or any other desired alteration of a biological system.
  • an “effective amount” is the amount of anti-C5 antibody, or antigen binding fragment thereof, clinically proven to alleviate at least one symptom of HSCT-TMA (e.g., microangiopathic hemolytic anemia, thrombocytopenia, endothelial injury, kidney damage, kidney failure, serositis, pulmonary hypertension, and multisystem organ failure).
  • An effective amount can be administered in one or more administrations.
  • loading dose refers to the intial doses administered during an administration cycle (e.g., on Days 1, 5, and 10).
  • maintenance and “maintenance phase” are used interchangeably and refer to the second phase of treatment (e.g., doses administered every eight weeks starting at Day 15). In certain embodiments, treatment is continued as long as clinical benefit is observed or until unmanageable toxicity or disease progression occurs.
  • supplemental dose refers to an additional dose administered to an HSCT-TMA patient (e.g., having a body weight >30 kg) who received a RBC transfusion in the 4 weeks following a maintenance dose.
  • blood transfusion refers to a procedure in which whole blood or parts of blood are put into a patient’s bloodstream, e.g., through a vein. The blood may be donated by another person or it may have been taken from the patient and stored until needed.
  • red blood cell (RBC) transfusion refers to a transfusion of red blood cells, i.e., concentrated ery throcytes obtained from donated whole blood or by donor apheresis, into a patient’s bloodstream, e.g., through a vein.
  • the majonty of RBC transfusions are by infusion of packed RBCs that are prepared either by removing plasma from whole blood collection or by apheresis, followed by storage with additives to enhance cell viability and storage.
  • serum trough level refers to the lowest level that the agent (e.g., the anti-C5 antibody, or antigen binding fragment thereof) or medicine is present in the serum.
  • a “peak serum level,” refers to the highest level of the agent in the serum.
  • the “average serum level,” refers to the mean level of the agent in the serum over time.
  • antibody describes a polypeptide comprising at least one antibody-derived antigen binding site (e.g, VH/VL region or Fv, or CDR).
  • Antibodies include known forms of antibodies, e.g., the antibody can be a human antibody, a humanized antibody, a bispecific antibody or a chimeric antibody.
  • the antibody also can be a Fab, Fab’2, ScFv, SMIP, Affibody®, nanobody or a single-domain antibody.
  • the antibody also can be of any of the following isotypes: TgGl , IgG2, IgG3, TgG4, IgM, TgAl, IgA2, TgAsec, TgD, TgE or combinations thereof.
  • the antibody can be a naturally occurring antibody or an antibody that has been altered by a protein engineering technique (e.g., by mutation, deletion, substitution, conjugation to a non-antibody moiety).
  • An antibody can include, for example, one or more variant amino acids (compared to a naturally occurring antibody) that change a property (e.g, a functional property) of the antibody. Numerous such alterations are known in the art that affect, e.g., half-life, effector function, and/or immune responses to the antibody in a patient.
  • the term antibody also includes artificial or engineered polypeptide constructs that comprise at least one antibody -derived antigen binding site.
  • Anti-C5 antibodies described herein bind to complement component C5 (e.g, human C5) and inhibit the cleavage of C5 into fragments C5a and C5b. As described above, such antibodies also have, for example, improved pharmacokinetic properties relative to other anti-C5 antibodies (e.g., eculizumab) used for therapeutic purposes.
  • complement component C5 e.g, human C5
  • eculizumab eculizumab
  • Anti-C5 antibodies (or VH/VL domains derived therefrom) suitable for use in the methods described herein can be generated using methods known in the art. Alternatively, art recognized anti-C5 antibodies can be used. Antibodies that compete for binding to C5 with any of these art recognized antibodies or antibodies described herein can also be used.
  • An exemplary anti-C5 antibody is ravuhzumab comprising heavy and light chains having the sequences shown in SEQ ID NOs: 14 and 11 , respectively, or antigen binding fragments and variants thereof.
  • Ravulizumab also known as ULTOMIRIS®, BNJ441 and ALXN1210
  • WO2015134894 and US Patent No: 9,079,949, the entire teachings of which are hereby incorporated by reference.
  • the terms ravuhzumab, BNJ441, and ALXN1210 may be used interchangeably throughout this document, but all refer to the same antibody.
  • Ravulizumab selectively binds to human complement protein C5, inhibiting its cleavage to C5a and C5b during complement activation.
  • This inhibition prevents the release of the proinflammatory mediator C5a and the formation of the cytolytic pore-forming membrane attack complex (MAC) C5b-9 while preserving the proximal or early components of complement activation (e.g., C3 and C3b) essential for the opsonization of microorganisms and clearance of immune complexes.
  • MAC cytolytic pore-forming membrane attack complex
  • the polypeptide sequence of ravulizumab provides that the N-termmal amino acid of variable heavy chain is “X”, but the database does not state what X is.
  • the Chemical Abstracts (CAS) for ravulizumab (CAS 1803171-55-2) also provides that N-terminal X is pyroglutamic acid (designated as “chain 1 pyroglutamic acid-1” in the CAS report).
  • VH sequence of ravulizumab e.g., a heavy chain variable region polypeptide comprising the amino acid sequence depicted in SEQ ID NO: 12 and/or a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO: 14, there is alignment between patented sequences and the drug database/CAS sequence because it was recognized in the art that N-Terminal Q in polypeptide and/or antibody sequence cyclizes during process development to yield drug product conversion to pyroglutamate (Pryo-Q) near 100%, as disclosed in Liu et al. (J Pharm Sci .
  • the antibody comprises the heavy and light chain CDRs or variable regions of ravulizumab. Accordingly, in one embodiment, the antibody comprises the CDR1, CDR2 and CDR3 domains of the VH region of ravulizumab having the sequence set forth in SEQ ID NO: 12, and the CDR1, CDR2 and CDR3 domains of the VL region of ravulizumab having the sequence set forth in SEQ ID NO: 8. In another embodiment, the antibody comprises heavy chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 19, 18 and 3, respectively, and light chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:4, 5 and 6, respectively. In another embodiment, the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO: 8, respectively.
  • antibody BNJ421 comprising heavy and light chains having the sequences shown in SEQ ID NOs:20 and 11, respectively, or antigen binding fragments and variants thereof.
  • BNJ421 also known as ALXN1211
  • ALXN1211 is described in WO2015134894 and US Patent No.9,079,949, the entire teachings of which are hereby incorporated by reference.
  • the antibody comprises the heavy and light chain CDRs or variable regions of BNJ421. Accordingly, in one embodiment, the antibody comprises the CDR1, CDR2 and CDR3 domains of the VH region of BNJ421 having the sequence set forth in SEQ ID NO: 12, and the CDR1, CDR2 and CDR3 domains of the VL region of BNJ421 having the sequence set forth in SEQ ID NO: 8. In another embodiment, the antibody comprises heavy chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 19, 18 and 3, respectively, and light chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:4, 5 and 6, respectively. In another embodiment, the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO: 8, respectively.
  • CDRs are defined differently according to different methods.
  • the positions of the CDRs or framework regions within a light or heavy chain variable domain are as defined by Kabat et al. [(1991) “Sequences of Proteins of Immunological Interest.” NIH Publication No. 91-3242, U.S. Department of Health and Human Services, Bethesda, MDJ.
  • the CDRs can be referred to as “Kabat CDRs” (e.g., “Kabat LCDR2” or “Kabat HCDR1”).
  • the positions of the CDRs of a light or heavy chain variable region are as defined by Chothia et al. (Nature, 342:877-83, 1989).
  • these regions can be referred to as “Chothia CDRs” (e.g., “Chothia LCDR2” or “Chothia HCDR3”).
  • the positions of the CDRs of the light and heavy chain variable regions can be defined by a Kabat-Chothia combined definition.
  • these regions can be referred to as “combined Kabat-Chothia CDRs.” Thomas, C. et al. (Mol. Immunol., 33: 1389-401, 1996) exemplifies the identification of CDR boundaries according to Kabat and Chothia numbering schemes.
  • Another exemplary anti-C5 antibody is the 7086 antibody described in US Patent Nos. 8,241,628 and 8,883,158.
  • the antibody comprises the heavy and light chain CDRs or variable regions of the 7086 antibody (see US Patent Nos. 8,241,628 and 8,883,158).
  • the antibody, or antigen binding fragment thereof comprises heavy chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:21, 22 and 23, respectively, and light chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:24, 25 and 26, respectively.
  • the antibody, or antigen binding fragment thereof comprises the VH region of the 7086 antibody having the sequence set forth in SEQ ID NO:27, and the VL region of the 7086 antibody having the sequence set forth in SEQ ID NO:28.
  • the antibody comprises the heavy and light chain CDRs or variable regions of the 8110 antibody.
  • the antibody, or antigen binding fragment thereof comprises heavy chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:29, 30 and 31, respectively, and light chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:32, 33 and 34, respectively.
  • the antibody comprises the VH region of the 8110 antibody having the sequence set forth in SEQ ID NO:35, and the VL region of the 8110 antibody having the sequence set forth in SEQ ID NO:36.
  • the antibody comprises the heavy and light chain CDRs or variable regions of the 305LO5 antibody.
  • the antibody, or antigen binding fragment thereof comprises heavy chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:37, 38 and 39, respectively, and light chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:40, 41 and 42, respectively.
  • the antibody comprises the VH region of the 305LO5 antibody having the sequence set forth in SEQ ID NO:43, and the VL region of the 305LO5 antibody having the sequence set forth in SEQ ID NO:44.
  • Another exemplary anti-C5 antibody is the SKY59 antibody (Fukuzawa, T. et al., Set. Rep., 7: 1080, 2017).
  • the antibody comprises the heavy and light chain CDRs or variable regions of the SKY59 antibody.
  • the antibody, or antigen binding fragment thereof comprises a heavy chain comprising SEQ ID NO:45 and a light chain comprising SEQ ID NO:46.
  • the anti-C5 antibody comprises the heavy and light chain variable regions or heavy and light chains of the REGN3918 antibody (see US Patent No. 10,633,434).
  • the anti-C5 antibody, or antigen-binding fragment thereof comprises a heavy chain variable region sequence set forth in SEQ ID NO: 47 and a light chain variable region comprising the sequence set forth in SEQ ID NO: 48.
  • the anti-C5 antibody, or antigen-binding fragment thereof comprises a heavy chain sequence set forth in SEQ ID NO: 49 and a light chain sequence set forth in SEQ ID NO: 50.
  • the anti-C5 antibody is a biosimilar of eculizumab (SOLIRIS®).
  • the anti-C5 antibody is, for example, ABP 959 antibody (eculizumab biosimilar manufactured by Amgen Inc., USA), ELIZ ARIA® (eculizumab biosimilar manufactured by Generium JNC, Russia), SB12 (eculizumab biosimilar manufactured by Samsung Bioepis, Incheon, South Korea), ISU305 (eculizumab biosimilar from ISU Abxis, South Korea), ABLYZE® (eculizumab biosimilar from CinnaGen, Iran), BCD 148 (eculizumab biosimilar from Biocad Medical, Quebec, Canada), tesidolumab (manufactured by Novartis), Crovalimab (manufactured by Roche), CAN106 (manufactured by CanBridge Pharmaceuticals, China), or Pozelimab (manufactured by Regeneron).
  • ABP 959 antibody
  • an anti-C5 antibody described herein comprises a heavy chain CDR1 comprising, or consisting of, the following amino acid sequence: GHIFSNYWIQ (SEQ ID NO: 19).
  • an anti-C5 antibody described herein comprises a heavy chain CDR2 comprising, or consisting of, the following amino acid sequence: EILPGSGHTEYTENFKD (SEQ ID NO: 18).
  • an anti-C5 antibody described herein comprises a heavy chain variable region comprising the following amino acid sequence:
  • an anti-C5 antibody described herein comprises a light chain variable region comprising the following amino acid sequence:
  • An anti-C5 antibody described herein can, in some embodiments, comprise a variant human Fc constant region that binds to human neonatal Fc receptor (FcRn) with greater affinity than that of the native human Fc constant region from which the variant human Fc constant region was derived.
  • the Fc constant region can, for example, comprise one or more (e.g., two, three, four, five, six, seven, or eight or more) amino acid substitutions relative to the native human Fc constant region from which the variant human Fc constant region was derived. The substitutions can increase the binding affinity of an IgG antibody containing the variant Fc constant region to FcRn at pH 6.0, while maintaining the pH dependence of the interaction.
  • substitutions that enhance the binding affinity of an antibody Fc constant region for FcRn include, e.g., (1) the M252Y/S254T/T256E triple substitution (Dall’Acqua, W. et al., J. Biol. Chem., 281 :23514-24, 2006); (2) the M428L or T250Q/M428L substitutions (Hinton, P. et al., J. Biol. Chem., 279:6213-6. 2004; Hinton, P. et al., J. Immunol., 176:346-56, 2006); and (3) the N434A or T307/E380A/N434A substitutions (Petkova, S.
  • the variant constant region has a substitution at EU ammo acid posaition 255 for valine. In some embodiments, the variant constant region has a substitution at EU amino acid position 309 for asparagine. In some embodiments, the variant constant region has a substitution at EU amino acid position 312 for isoleucine. In some embodiments, the variant constant region has a substitution at EU amino acid position 386.
  • the variant Fc constant region comprises no more than 30 (e.g., no more than 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 or 2) amino acid substitutions, insertions, or deletions relative to the native constant region from which it was derived.
  • the variant Fc constant region comprises one or more amino acid substitutions selected from the group consisting of: M252Y, S254T, T256E, N434S, M428L, V259I, T250I and V308F.
  • the variant human Fc constant region comprises a methionine at position 428 and an asparagine at position 434 of a native human IgG Fc constant region, each in EU numbering.
  • the variant Fc constant region comprises a 428L/434S double substitution as described in, e.g., U.S. Patent No. 8,088,376.
  • the precise location of these mutations may be shifted from the native human Fc constant region position due to antibody engineering.
  • the 428E/434S double substitution when used in a IgG2/4 chimeric Fc may correspond to 429L and 435S as in the M429L and N435S variants found in ravulizumab and described in US Patent Number 9,079,949 the disclosure of which is incorporated herein by reference in its entirety.
  • the variant constant region comprises a substitution at amino acid position 237, 238, 239, 248, 250, 252, 254, 255, 256, 257, 258, 265, 270, 286, 289, 297, 298, 303, 305, 307, 308, 309, 311, 312, 314, 315, 317, 325, 332, 334, 360, 376, 380, 382, 384, 385, 386, 387, 389, 424, 428, 433, 434 or 436 (EU numbering) relative to the native human Fc constant region.
  • the substitution is selected from the group consisting of: methionine for glycine at position 237; alanine for proline at position 238; lysine for serine at position 239; isoleucine for lysine at position 248; alanine, phenylalanine, isoleucine, methionine, glutamine, serine, valine, tryptophan, or tyrosine for threonine at position 250; phenylalanine, tryptophan, or tyrosine for methionine at position 252; threonine for serine at position 254; glutamic acid for arginine at position 255; aspartic acid, glutamic acid, or glutamine for threonine at position 256; alanine, glycine, isoleucine, leucine, methionine, asparagine, serine, threonine, or valine for proline at position 257; histidine for
  • Suitable anti-C5 antibodies for use in the methods described herein comprise a heavy chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 14 and/or a light chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 11.
  • the anti-C5 antibodies for use in the methods described herein in some embodiments, comprise a heavy chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO:20 and/or a light chain polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 11.
  • the antibody binds to C5 at pH 7.4 and 25°C (and, otherwise, under physiologic conditions) with an affinity dissociation constant (KD) that is at least 0. 1 (e.g., at least 0.15, 0.175, 0.2, 0.25, 0.275, 0.3, 0.325, 0.35, 0.375, 0.4, 0.425, 0.45, 0.475, 0.5, 0.525, 0.55, 0.575, 0.6, 0.625, 0.65, 0.675, 0.7, 0.725, 0.75, 0.775, 0.8, 0.825, 0.85, 0.875, 0.9, 0.925, 0.95, or 0.975) nM.
  • KD affinity dissociation constant
  • the antibody binds to C5 at pH 7.4 and 25°C (and, otherwise, under physiologic conditions) with an affinity dissociation constant (KD) that is about 0.5 nM.
  • KD affinity dissociation constant
  • the KD of the anti-C5 antibody, or antigen binding fragment thereof is no greater than 1 (e.g., no greater than 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, or 0.2) nM.
  • the antibody binds to C5 at pH 6.0 and 25°C (and, otherwise, under physiologic conditions) with a KD that is about 22 nM.
  • the [(KD of the antibody for C5 at pH 6.0 at 25°C)/(KD of the antibody for C5 at pH 7.4 at 25C)] is greater than 21 (e.g., greater than 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500 or 8000)
  • binding of an antibody to a protein antigen can be detected and/or quantified using a variety of techniques such as, but not limited to, Western blot, dot blot, surface plasmon resonance (SPR) detection (e.g., BIAcore system; Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.), or enzyme-linked immunosorbent assay (ELISA; Benny K. C. Lo (2004) “Antibody Engineering: Methods and Protocols,” Humana Press (ISBN: 1588290921); Johne, B. et al., J.
  • SPR surface plasmon resonance
  • the term “k a ” refers to the rate constant for association of an antibody to an antigen.
  • the term “kd” refers to the rate constant for dissociation of an antibody from the antibody/antigen complex.
  • KD refers to the equilibrium dissociation constant of an antibody -antigen interaction.
  • Such determinations can be measured, for example, at 25C or 37C (see the working examples).
  • the kinetics of antibody binding to human C5 can be determined, for example, at pH 8.0, 7.4, 7.0, 6.5 and 6.0 via SPR on a BIAcore 3000 instrument using an anti-Fc capture method to immobilize the antibody.
  • the anti-C5 antibody, or antigen binding fragment thereof blocks the cleavage of C5 into C5a and C5b.
  • this blocking effect for example, the pro-inflammatory effects of C5a and the generation of the C5b-9 membrane attack complex (MAC) at the surface of a cell are inhibited.
  • MAC membrane attack complex
  • Inhibition of human complement component C5 can reduce the cell-lysing ability of complement in a subject’s body fluids.
  • Such reductions of the cell-lysing ability of complement present in the body fluid(s) can be measured by methods known in the art such as, for example, by a conventional hemolytic assay such as the hemolysis assay (Kabat and Mayer (eds.), “Experimental Immunochemistry, 2 nd Edition,” 135-240, Springfield, IL, CC Thomas (1961), pages 135-139), or a conventional variation of that assay such as the chicken erythrocyte hemolysis method (Hillmen, P. et al., N.
  • Immunological techniques such as, but not limited to, ELISA can be used to measure the protein concentration of C5 and/or its split products to determine the ability of an anti-C5 antibody, or antigen binding fragment thereof, to inhibit conversion of C5 into biologically active products.
  • C5a generation is measured.
  • C5b-9 neoepitope-specific antibodies are used to detect MAC formation.
  • Hemolytic assays can be used to determine the inhibitory activity of an anti-C5 antibody, or antigen binding fragment thereof, on complement activation.
  • an anti-C5 antibody, or antigen binding fragment thereof, on classical complement pathway -mediated hemolysis in a serum test solution in vitro for example, sheep erythrocytes coated with hemolysin or chicken erythrocytes sensitized with anti-chicken erythrocyte antibody are used as target cells. The percentage of lysis is normalized by considering 100% lysis equal to the lysis occurring in the absence of the inhibitor.
  • the classical complement pathway is activated by a human IgM antibody, for example, as utilized in the Wieslab® Classical Pathway Complement Kit (Wieslab® COMPL CP310, Euro-Diagnostica, Sweden). Briefly, the test serum is incubated with an anti-C5 antibody, or antigen binding fragment thereof, in the presence of a human IgM antibody. The amount of C5b-9 that is generated is measured by contacting the mixture with an enzyme conjugated anti-C5b-9 antibody and a fluorogenic substrate and measuring the absorbance at the appropriate wavelength. As a control, the test serum is incubated in the absence of the anti-C5 antibody, or antigen binding fragment thereof. In some embodiments, the test serum is a C5-deficient serum reconstituted with a C5 polypeptide.
  • the serum test solution is a C5-deficient serum reconstituted with a C5 polypeptide.
  • the percentage of lysis is normalized by considering 100% lysis equal to the lysis occurring in the absence of the inhibitor.
  • the alternative complement pathway is activated by lipopolysaccharide molecules, for example, as utilized in the Wieslab® Alternative Pathway Complement Kit (Wieslab® COMPL AP330, Euro-Diagnostica, Sweden).
  • test serum is incubated with an anti-C5 antibody, or antigen binding fragment thereof, in the presence of lipopolysaccharide.
  • the amount of C5b-9 that is generated is measured by contacting the mixture with an enzyme conjugated anti-C5b-9 antibody and a fluorogenic substrate and measuring the fluorescence at the appropriate wavelength.
  • test serum is incubated in the absence of the anti-C5 antibody, or antigen binding fragment thereof.
  • C5 activity, or inhibition thereof is quantified using a CH50eq assay.
  • the CH50eq assay is a method for measuring the total classical complement activity in serum. This test is a lytic assay, which uses antibody-sensitized ery throcytes as the activator of the classical complement pathway and various dilutions of the test serum to determine the amount required to give 50% lysis (CH50). The percent hemolysis can be determined, for example, using a spectrophotometer.
  • the CH50eq assay provides an indirect measure of terminal complement complex (TCC) formation, since the TCC themselves are directly responsible for the hemolysis that is measured.
  • TCC terminal complement complex
  • undiluted serum samples e.g., reconstituted human serum samples
  • microassay wells containing the antibody-sensitized erythrocytes to thereby generate TCC.
  • the activated sera are diluted in microassay wells, which are coated with a capture reagent (e.g., an antibody that binds to one or more components of the TCC).
  • the TCC present in the activated samples bind to the monoclonal antibodies coating the surface of the microassay wells.
  • the wells are washed and to each well is added a detection reagent that is delectably labeled and recognizes the bound TCC.
  • the detectable label can be, e.g., a fluorescent label or an enzymatic label.
  • the assay results are expressed in CH50 unit equivalents per milliliter (CH50 U Eq/mL)
  • Inhibition e.g., as it pertains to terminal complement activity, includes at least a 5 (e.g., at least a 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 or 60) % decrease in the activity of terminal complement in, e.g, a hemolytic assay or CH50eq assay as compared to the effect of a control antibody (or antigen-binding fragment thereof) under similar conditions and at an equimolar concentration.
  • Substantial inhibition refers to inhibition of a given activity (e.g., terminal complement activity) of at least 40 (e.g, at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 or greater) %.
  • an anti-C5 antibody described herein contains one or more ammo acid substitutions relative to the CDRs of eculizumab (z.e., SEQ ID NOs:l-6), yet retains at least 30 (e.g., at least 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,
  • An anti-C5 antibody described herein has a serum half-life in humans that is at least 20 (e.g, at least 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,
  • the anti-C5 antibody described herein has a serum half-life in humans that is at least 40 days. In another embodiment, the anti-C5 antibody described herein has a serum half-life in humans that is approximately 43 days. In another embodiment, the anti-C5 antibody described herein has a serum half-life in humans that is between 39-48 days. Methods for measuring the serum half-life of an antibody are known in the art.
  • an anti-C5 antibody, or antigen binding fragment thereof, described herein has a serum half-life that is at least 20 (e.g., at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 400 or 500) % greater than the serum half-life of eculizumab, e.g., as measured in one of the mouse model systems described in the working examples (e.g., the C5-deficient/NOD/scid mouse or hFcRn transgenic mouse model system).
  • the antibody competes for binding with, and/or binds to the same epitope on C5 as an antibody described herein.
  • the term “binds to the same epitope” with reference to two or more antibodies means that the antibodies bind to the same segment of amino acid residues, as determined by a given method.
  • Techniques for determining whether antibodies bind to the same epitope on C5 with an antibody described herein include, for example, epitope mapping methods, such as, x-ray analyses of crystals of antigen: antibody complexes, and hydrogen/ deuterium exchange mass spectrometry (HDX-MS).
  • Antibodies having the same VH and VL or the same CDR1 , CDR2 and CDR3 sequences are expected to bind to the same epitope.
  • Antibodies that “compete with another antibody for binding to a target” refer to antibodies that inhibit (partially or completely) the binding of the other antibody to the target. Whether two antibodies compete with each other for binding to a target, i.e., whether and to what extent one antibody inhibits the binding of the other antibody to a target, may be determined using known competition experiments. In certain embodiments, an antibody competes with, and inhibits binding of another antibody to a target by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. The level of inhibition or competition may be different depending on which antibody is the “blocking antibody” (i.e., the antibody that is incubated first with the target). Competing antibodies can bind to, for example, the same epitope, an overlapping epitope or to adjacent epitopes (e.g., as evidenced by steric hindrance).
  • Anti-C5 antibodies, or antigen-binding fragments thereof described herein, used in the methods described herein can be generated using a variety of art-recognized techniques. Monoclonal antibodies can be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (Kohler, G. & Milstein, C., Eur. J. Immunol., 6:511-9, 1976)). Methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses or other methods known in the art.
  • Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host.
  • compositions comprising an anti-C5 antibody or antigen binding fragment thereof.
  • the composition comprises an anti-C5 antibody comprising the CDR1, CDR2 and CDR3 domains in a heavy chain variable region having the sequence set forth in SEQ ID NO: 12, and the CDR1, CDR2 and CDR3 domains in a light chain variable region having the sequence set forth in SEQ ID NO: 8.
  • the anti-C5 antibody comprises heavy and light chains having the sequences shown in SEQ ID NOs: 14 and 11, respectively.
  • the anti-C5 antibody comprises heavy and light chains having the sequences shown in SEQ ID NOs:20 and 11, respectively.
  • compositions can be formulated as a pharmaceutical solution, e.g, for administration to a subject for the treatment of HSCT-TMA.
  • the pharmaceutical compositions generally include a pharmaceutically acceptable carrier.
  • a “pharmaceutically acceptable carrier” refers to, and includes, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • the compositions can include a pharmaceutically acceptable salt, e.g., an acid addition salt or a base addition salt, sugars, carbohydrates, polyols and/or tonicity modifiers.
  • compositions can be formulated according to standard methods.
  • Pharmaceutical formulation is an established art (see, for example, Gennaro (2000) “Remington: The Science and Practice of Pharmacy,” 20 th Edition, Lippincott, Williams & Wilkins (ISBN: 0683306472); Ansel et al. (1999) “Pharmaceutical Dosage Forms and Drug Delivery Systems,” 7 th Edition, Lippincott Williams & Wilkins Publishers (ISBN: 0683305727); and Kibbe (2000) “Handbook of Pharmaceutical Excipients American Pharmaceutical Association,” 3 rd Edition (ISBN: 091733096X)).
  • a composition can be formulated, for example, as a buffered solution at a suitable concentration and suitable for storage at 2-8C (e.g., 4C). In some embodiments, a composition can be formulated for storage at a temperature below OC (e.g., -20C or -80C). In some embodiments, the composition can be formulated for storage for up to 2 years (e.g., 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 1 ! years or 2 years) at 2-8C (e.g, 4C). Thus, in some embodiments, the compositions described herein are stable in storage for at least 1 year at 2-8C (e.g., 4C).
  • compositions can be in a variety of forms. These forms include, e.g., liquid, semi-sohd and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories.
  • liquid solutions e.g., injectable and infusible solutions
  • dispersions or suspensions tablets, pills, powders, liposomes and suppositories.
  • the preferred form depends, in part, on the intended mode of administration and therapeutic application.
  • Compositions containing a composition intended for systemic or local delivery for example, can be in the form of injectable or infusible solutions. Accordingly, the compositions can be formulated for administration by a parenteral mode (e.g, intravenous, subcutaneous, intraperitoneal, or intramuscular injection).
  • parenteral mode e.g, intravenous, subcutaneous, intraperitoneal, or intramuscular injection.
  • Parenteral administration refers to modes of administration other than enteral and topical administration, usually by injection, and include, without limitation, intravenous, intranasal, intraocular, pulmonary, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intrapulmonary, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, intracerebral, intracranial, intracarotid and intrastemal injection and infusion.
  • HSCT-TMA in a particular patient subpopulation
  • a transfusion e.g., platelet or RBC transfusion
  • a particular clinical dosage regimen e.g., at particular loading, maintenance, and one or more supplemental dose amounts, and according to a specific schedule.
  • the dose of the anti-C5 antibody, or antigen binding fragment thereof is based on the weight of the patient.
  • a 300 mg or 600 mg loading dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 5 to ⁇ 10 kg.
  • a 400 mg maintenance dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 5 to ⁇ 10 kg.
  • a 400 mg supplemental dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 5 to ⁇ 10 kg.
  • a 300 mg or 600 mg loading dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 10 to ⁇ 20 kg.
  • a 800 mg maintenance dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 10 to ⁇ 20 kg.
  • a 800 mg supplemental dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 10 to
  • a 300 mg or 900 mg loading dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 20 to ⁇ 30 kg.
  • a 2100 mg maintenance dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 20 to ⁇ 30 kg.
  • a 2100 mg supplemental dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 20 to ⁇ 30 kg.
  • a 300 mg or 1200 mg loading dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 30 to
  • a 2700 mg maintenance dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patent weighing > 30 to ⁇ 40 kg.
  • a 2700 mg supplemental dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 30 to ⁇ 40 kg.
  • a 600 mg or 2400 mg loading dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 40 to ⁇ 60 kg.
  • a 3000 mg maintenance dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 40 to ⁇ 60 kg.
  • a 3000 mg supplemental dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 40 to ⁇ 60 kg.
  • a 900 mg or 2700 mg loading dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patent weighing > 60 to ⁇ 100 kg.
  • a 3300 mg maintenance dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 60 to ⁇ 100 kg.
  • a 3300 mg supplemental dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 60 to ⁇ 100 kg.
  • a 900 mg or 3000 mg loading dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 100 kg.
  • a 3600 mg maintenance dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 100 kg.
  • a 3600 mg supplemental dose of the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing > 100 kg.
  • dosage regimens are adjusted to provide the optimum desired response (e.g., an effective response).
  • the patient receives a post-transfusion supplemental dose of the anti-C5 antibody (e.g., ravulizumab) once only at the mid-way point between 2 maintenance doses.
  • the maintenance doses are administered every four weeks (Q4W) for lower (e.g., ⁇ 20 kg) weight class and every eight weeks (Q8W) for higher (e.g., >20 kg) weight class
  • the supplemental dose of the anti-C5 antibody is administered after week 2 ( ⁇ 20 kg patients) and after week 4 (>20 kg patients), e.g., 14 days or 28 days after the maintenance dose.
  • a post-transfusion supplemental dose of the anti-C5 antibody, or antigen binding fragment thereof, is administered to the HSCT-TMA patient once only 4 weeks after the last maintenance dose, if any amount of RBC transfusion is provided to the patient within the 4 weeks after the last maintenance dose.
  • the anti-C5 antibody, or antigen binding fragment thereof is administered for one or more administration cycles.
  • the treatment e.g., administration cycle
  • the treatment is 26 weeks.
  • the anti-C5 antibody, or antigen binding fragment thereof is administered at a loading dose once on Day 1 (e.g., of the administration cycle), once on Day 5 (e.g., of the administration cycle), once on Day 10 (e.g, of the administration cycle).
  • the anti-C5 antibody, or antigen binding fragment thereof is administered is administered a loading dose once on Day 1 (e.g., of the administration cycle), at a loading dose once on Day 5 (e.g, of the administration cycle), at a loading dose once on Day 10 (e.g, of the administration cycle) and a maintenance dose every eight weeks thereafter starting at Day 15.
  • the anti-C5 antibody, or antigen binding fragment thereof is administered every eight weeks after treatment (e.g., an administration cycle) for an extension period up to two years (e.g., at a dose of 300 mg, 600 mg, 900 mg, 1200 mg, 2100 mg, 2400 mg, 2700 mg, 3000 mg, 3300 mg or 3600 mg).
  • a supplemental dose is administered to a patient who receives a transfusion (e.g. , platelet or RBC transfusion) within two weeks or four weeks of a maintenance dose, wherein the supplemental dose is administered two weeks or four weeks after that maintenance dose.
  • a supplemental dose is administered to a patient weighing ⁇ 20 kg who receives a RBC transfusion within two weeks of a maintenance dose, wherein the supplemental dose is administered two weeks after that maintenance dose at a dose of: 400 mg to a patient weighing > 5 to ⁇ 10 kg, 800 mg to a patient weighing > 10 to ⁇ 20 kg.
  • a supplemental dose is administered to a patient weighing > 20 ⁇ 30 kg who receives a RBC transfusion within four weeks of a maintenance dose, wherein the supplemental dose is administered four weeks after that maintenance dose at a dose of: 2100 mg to a patient weighing > 20 ⁇ 30 kg.
  • a supplemental dose is administered to a patient weighing > 30 kg who receives a RBC transfusion within four weeks of a maintenance dose, wherein the supplemental dose is administered four weeks after that maintenance dose at a dose of: 2700 mg to a patient w eighing > 30 to ⁇ 40 kg, 3000 mg to a patient weighing > 40 to ⁇ 60 kg, 3300 mg to a patient weighing > 60 to ⁇ 100 kg, or 3600 mg to a patient weighing > 100 kg.
  • a method of treating a human patient with HSCT-TMA comprising administenng to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID N0s:4, 5 and 6, respectively, wherein the anti-C5 antibody or antigen binding fragment thereof, is administered:
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of an anti-C5 antibody comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively and a variant human Fc constant region that binds to human neonatal Fc receptor (FcRn), wherein the variant human Fc CH3 constant region comprises Met429Leu and Asn435Ser substitutions at residues corresponding to methionine 428 and asparagine 434 of a native human IgG Fc constant region, each according to the EU numbering convention, wherein the anti-C5 antibody is administered:
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of ravulizumab, wherein ravulizumab is administered:
  • a maintenance dose of: 2100 mg to a patient weighing 20 to ⁇ 30 kg, 2700 mg to a patient weighing > 30 to ⁇ 40 kg, 3000 mg to a patient weighing > 40 to ⁇ 60 kg, 3300 mg to a patient weighing > 60 to ⁇ 100 kg, or 3600 mg to a patient weighing > 100 kg; and wherein a supplemental dose is administered: (i) to a patient weighing ⁇ 30 kg who receives RBC transfusion within a specified timeframe of a maintenance dose, wherein the supplemental dose is administered at the specified timeframe following the maintenance dose, at a dose of: a.
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of ravulizumab, wherein ravulizumab is administered:
  • the treatment results in a reduction in LDH levels to within normal levels or to within 50% below what is considered the ULN level (e.g., within 105-333 IU/L (international units per liter), a serum trough concentration of the anti-C5 antibody, or antigen binding fragment thereof, of at least 175 pg/mL or greater, and/or a free C5 concentration of 0.5 pg/mL or less (e.g., 0.4 pg/mL, 0.3 pg/mL, 0.2 pg/mL, or 0.1 pg/mL or less).
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing 5 to ⁇ 10 kg:
  • an anti-C5 antibody, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab
  • a supplemental dose of 300 mg to a patient who receives RBC transfusion within two weeks of a maintenance dose, wherein the supplemental dose is administered two weeks after the maintenance dose.
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing 5 to ⁇ 10 kg:
  • an anti-C5 antibody, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab
  • a supplemental dose of 400 mg to a patient who receives RBC transfusion within two weeks of a maintenance dose and wherein the supplemental dose is administered two weeks after the maintenance dose.
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing 10 to ⁇ 20 kg:
  • an anti-C5 antibody, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab
  • a supplemental dose of 600 mg to a patient who receives RBC transfusion within two weeks of a maintenance dose and wherein the supplemental dose is administered two weeks after the maintenance dose.
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing 10 to ⁇ 20 kg:
  • an anti-C5 antibody, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing 20 to ⁇ 30 kg:
  • an anti-C5 antibody, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab
  • a supplemental dose of 2100 mg to a patient who receives RBC transfusion within two weeks of a maintenance dose and wherein the supplemental dose is administered four weeks after the maintenance dose.
  • the supplemental dose is administered if w arranted per a clinical algorithm as set forth in FIG. 3. In some embodiments, the supplemental dose is administered if warranted per a clinical algorithm as set forth in Table 7.
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient w eighing > 30 to ⁇ 40 kg:
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing > 40 to ⁇ 60 kg:
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing > 60 to ⁇ 100 kg:
  • an anti-C5 antibody, or antigen binding fragment thereof comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody or antigen binding fragment thereof (e.g., ravulizumab),
  • a method of treating a human patient with HSCT-TMA comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively, wherein the anti-C5 antibody or antigen binding fragment thereof (e.g., ravulizumab), is administered to a patient weighing > 100 kg:
  • immediate, complete, and sustained terminal complement inhibition is achieved following administration of a supplement dose of the anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab).
  • the methods of treatment disclosed herein further comprise administering best supportive care (BSC) measures.
  • BSC measures include, but are not limited to, transfusion support, corticosteroids, dialysis, and antihypertensive medications.
  • the patient has not previously been treated with eculizumab. In another embodiment, the patient has previously been treated with eculizumab. In another embodiment, the patient has previously been treated with eculizumab and Day 1 (e.g. , of the administration cycle) is two weeks or more from the patient’s last dose of eculizumab.
  • Day 1 e.g. , of the administration cycle
  • HSCT-TMA HSCT-TMA
  • Symptoms of HSCT-TMA include, but are not limited to, e.g., microangiopathic hemolytic anemia, thrombocytopenia, endothelial injury, kidney damage, kidney failure, serositis, pulmonary hypertension, and multisystem organ failure.
  • Patients treated according to the methods disclosed herein experience improvement in at least one sign of HSCT-TMA.
  • the treatment may produce at least one therapeutic effect selected from the group consisting of, for example, a reduction or cessation in microangiopathic hemolytic anemia, thrombocytopenia, endothelial injury, kidney damage, kidney failure, serositis, pulmonary hypertension, and multisystem organ failure compared to baseline.
  • the treatment results in (a) platelet count > 50,000/mm 3 without transfusion support during the prior 7 days, (b) LDH ⁇ 1.5 x ULN, and (c) absence of schistocytes (if there were schistocytes present at baseline).
  • the treatment results in (a) platelet count > 50,000/mm 3 without transfusion support during the prior 7 days, (b) LDH ⁇ 1.5 * ULN, (c) absence of schistocytes (if there were schistocytes present at baseline) and (d) at least 50% reduction of proteinuria from baseline.
  • proteinuria is as protein/creatinine ratio > 0.5 mg/mg.
  • the treatment results in a favorable hematological response.
  • the treatment results in normalization of LDH, resolution of need for red cell and platelet transfusions, and disappearance of schistocytes.
  • the treatment results in the patient’s ability to maintain hemoglobin > 8 g/dL without transfusion support. In another embodiment, the treatment results in hemoglobin > 8 g/dL without transfusion support.
  • the treatment results in a decrease in LDH, an increase in platelets, and/or an increase in hemoglobin compared to baseline.
  • the treatment results in normal levels of serum creatinine compared to baseline.
  • the treatment results in an improvement in TMA-associated organ dysfunction in the renal, cardiovascular, pulmonary, CNS, and/or GI systems compared to baseline.
  • the treatment results in terminal complement inhibition.
  • the treatment produces a reduction in adverse events.
  • the treatment produces a shift toward normal levels of biomarkers associated with vascular inflammation (e.g., shed tumor necrosis factor receptor 1 [TNF-R1]), endothelial damage and/or activation (e.g., thrombomodulin and shed vascular cell adhesion molecule 1 [VCAM-1]), renal injury' (e.g., Cystatin C), and/or complement proteins and complement activation pathway products.
  • the treatment produces a shift toward normal levels of thrombomodulin (TM) and/or syndecan-1 (SYND1).
  • the treatment produces a shift toward normal levels of complement factor Ba.
  • the treatment produces a change from baseline in quality of life as assessed via a Quality of Life Assessment (e.g., a Quality of Life Inventory (PedsQL) Scale or an EQ-5D-5L questionnaire).
  • a Quality of Life Assessment e.g., a Quality of Life Inventory (PedsQL) Scale or an EQ-5D-5L questionnaire.
  • the PedsQL 4.0 Generic Core Scales are multidimensional child self-reports and parent proxy-report standardized instruments to measure health related quality of life (QoL) in children and adolescents 2-18 years of age.
  • lactate dehydrogenase (LDH) levels can be used to evaluate responsiveness to a therapy.
  • LDH is a marker of intravascular hemolysis (Hill, A. et al., Br. J. Haematol., 149:414-25, 2010; Hillmen, P. el al., N. Engl. J. Med., 350:552-9, 2004; Parker, C. et al., Blood, 106:3699-709, 2005).
  • Red blood cells contain large amounts of LDH, and a correlation between cell-free hemoglobin and LDH concentration has been reported in vitro (Van Lente, F. et al., Clin.
  • LDH levels can be measured using any suitable test or assay, such as those described by Ferri FF, ed. Ferri's Clinical Advisor 2014. Philadelphia: Pa: Elsevier Mosby; 2014: Section IV- Laboratory tests and interpretation of results.
  • LDH concentration can be measured in various samples obtained from a patient, in particular, serum samples.
  • serum samples refers to biological material from a subject.
  • samples can be derived from other sources, including, for example, single cells, multiple cells, tissues, tumors, biological fluids, biological molecules or supernatants or extracts of any of the foregoing.
  • Examples include tissue removed for biopsy, tissue removed during resection, blood, urine, lymph tissue, lymph fluid, cerebrospinal fluid, mucous and stool samples.
  • the sample used can vary based on the assay format, the detection method and the nature of the tumors, tissues, cells or extracts to be assayed. Methods for preparing samples are known in the art and can be readily adapted to obtain a sample that is compatible with the method utilized. In one embodiment, patients treated according to the disclosed methods experience reductions in LDH levels to normal levels or to within 10%, or within 20% above what is considered the normal level (e.g., within 105-333 IU/L).
  • patients treated according to the disclosed methods experience reductions in LDH levels to within normal levels or to within 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% or within 50% below what is considered the ULN level (e g., within 105-333 IU/L (international units per liter).
  • the patient’s LDH levels are > 1.5 fold above the ULN (LDH > 1.5 x ULN) prior to initiating treatment.
  • patients treated according to the disclosed methods experience an LDH percent change compared to baseline of 10%, 1 1 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53% 54%, 55%, 56%, 57%, 58%, 59%, or 60%.
  • the treatment regimens described are sufficient to maintain particular serum trough concentrations of the anti-C5 antibody or antigen binding fragment thereof.
  • the treatment regimen maintains a serum trough concentration of the anti-C5 antibody or antigen binding fragment thereof of 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 200, 205, 210, 215, 220, 225, 230, 240, 245, 250, 255, 260, 265, 270,
  • the treatment regimen maintains a serum trough concentration of the anti-C5 antibody or antigen binding fragment thereof of 100 pg/mL or greater, 150 pg/mL or greater, 200 pg/mL or greater, 250 pg/mL or greater, 300 pg/mL or greater, 350 pg/mL or greater, 400 pg/mL or greater, or 450 pg/mL or greater.
  • the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen binding fragment thereof of between 100 pg/mL and 700 pg/mL; preferably between 300 pg/mL and 600 pg/mL. In another embodiment, the treatment maintains a serum trough concentration of the anti-C5 antibody or antigen binding fragment thereof of about 475 pg/mL.
  • the treatment regimen maintains a serum peak concentration of the anti-C5 antibody or antigen binding fragment thereof of less than about 1800, 1780, 1760, 1740, 1720, 1700, 1680, 1660, 1640, 1620, 1600, 1580, 1560, 1540, 1520, 1500, 1480, 1460, 1440, 1420, 1400, 1380, 1360, 1340, 1320, 1300, 1280, 1260, 1240, 1220, 1200, 1180, 1160, 1140, 1120, 1100, 1080, 1060, 1040, 1020, 1000, 980, 960, 940, 920, or 900 pg/mL, or less.
  • the treatment maintains a peak serum concentration of the anti-C5 antibody or antigen binding fragment thereof of between 900 pg/mL and 1800 pg/mL; preferably between 1050 pg/mL and 1550 pg/mL. In another embodiment, the treatment maintains a peak serum concentration of the anti-C5 antibody or antigen binding fragment thereof of about 1350 pg/mL.
  • the anti-C5 antibody is administered to the patient in an amount and with a frequency to maintain at least 50 pg, 55 pg, 60 pg, 65 pg, 70 pg, 75 pg, 80 pg, 85 pg, 90 pg, 95 pg, 100 pg, 105 pg, 110 pg, 115 pg, 120 pg, 125 pg, 130 pg, 135 pg, 140 pg, 145 pg, 150 pg, 155 pg, 160 pg, 165 pg,
  • the anti-C5 antibody e.g., ravulizumab
  • the anti-C5 antibody is administered to the patient in an amount and with a frequency to maintain a minimum and maximum plasma concentration ( ⁇ standard deviation) of the anti-C5 antibody (e.g, ravulizumab) during a dosing interval that is preferably between 474 ( ⁇ 200) pg/mL and 1350 ( ⁇ 430) pg/mL, respectively.
  • patients treated according to the disclosed methods have a free C5 concentration of 0.5 pg/mL or less (e.g., 0.4 pg/mL, 0.3 pg/mL, 0.2 pg/mL, or 0.1 pg/mL or less).
  • patients treated according to the disclosed methods achieve an immediate, complete, and sustained terminal complement inhibition.
  • kits that include a pharmaceutical composition containing an anti-C5 antibody or antigen binding fragment thereof, such as ravulizumab, and a pharmaceutically acceptable carrier, in a therapeutically effective amount adapted for use in the preceding methods.
  • the kits optionally also can include instructions, e.g., comprising administration schedules, to allow a practitioner (e.g., a physician, nurse, or patient) to administer the composition contained therein to administer the composition to a patient having HSCT-TMA.
  • the kit also can include a syringe.
  • kits include multiple packages of the single-dose pharmaceutical compositions each containing an effective amount of the anti-C5 antibody, or antigen binding fragment thereof, for a single administration in accordance with the methods provided above.
  • Instruments or devices necessary' for administering the pharmaceutical composition(s) also may be included in the kits.
  • a kit may provide one or more pre-filled syringes containing an amount of the anti-C5 antibody or antigen binding fragment thereof.
  • a kit for treating HSCT-TMA in a human pediatric patient comprises: (a) a dose of an anti-C5 antibody or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO: 12, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO: 8; and (b) instructions for using the anti-C5 anti body or antigen binding fragment thereof, according to any of the methods described herein.
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing 5 to ⁇ 10 kg:
  • a supplemental dose of 300 mg with instructions that the supplemental dose is administered to a patient who receives RBC transfusion within 2 weeks of a maintenance dose, wherein the supplemental dose is administered two weeks after the maintenance dose.
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing 5 to ⁇ 10 kg:
  • a supplemental dose of 400 mg with instructions that the supplemental dose is administered to a patient who receives RBC transfusion within 2 weeks of a maintenance dose, wherein the supplemental dose is administered two weeks after the maintenance dose.
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing 10 to ⁇ 20 kg:
  • a supplemental dose of 600 mg with instructions that the supplemental dose is administered to a patient who receives RBC transfusion within 2 weeks of a maintenance dose, wherein the supplemental dose is administered two weeks after the maintenance dose.
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing 10 to ⁇ 20 kg: (a) once on Day 1 at a loading dose of 600 mg;
  • a supplemental dose of 800 mg with instructions that the supplemental dose is administered to a patient who receives RBC transfusion within 2 weeks of a maintenance dose, wherein the supplemental dose is administered two weeks after a maintenance dose.
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof is administered to a patient weighing 20 to ⁇ 30 kg:
  • a supplemental dose of 2100 mg with instructions that the supplemental dose is administered to a patient who receives RBC transfusion within 4 weeks of a maintenance dose, wherein the supplemental dose is administered four weeks after the maintenance dose.
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing > 30 to ⁇ 40 kg:
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing > 40 to ⁇ 60 kg:
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing > 60 to ⁇ 100 kg:
  • the kit comprises loading, maintenance, and supplemental doses of an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a patient weighing > 100 kg:
  • EXAMPLE 1 Ravulizumab Dose Confirmation Analysis in Global Phase 3 Study to Assess Pharinacokinetics/Pharmacodynamics in Adults and Adolescents Who Developed Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
  • PK-PD pharmacokinetic-pharmacodynamic
  • Stage 1 of the phase 3 study of ravulizumab for the treatment of adults and adolescents (aged >12 years) with HSCT-TMA (NCT04543591) was an open-label, singlearm period designed to confirm the ravulizumab dose regimen. Participants received weightbased loading doses on Days 1, 5 and 10, followed by a maintenance dose on Day 15 and every 8 weeks thereafter. A supplemental dose was given within 24 hours after any platelet or red blood cell (RBC) transfusion. There was no limit on the number of supplemental doses. Blood samples for analysis were taken during the treatment period. Dose confirmation analysis (DC A) was performed once at least the first 10 patients enrolled had completed Day 21.
  • DC A Dose confirmation analysis
  • DCA involved three steps.
  • Step 1 PK and free C5 (primary PD) data were visualized. Previously established thresholds indicating complete C5 inhibition were used to empirically confirm that the dose regimen resulted in appropriate ravulizumab concentrations and was providing immediate, complete and sustained inhibition of free C5.
  • Step 2 population pharmacokinetic (popPK) modeling of ravulizumab concentration-time data. Body weight and transfusions were applied to a previously developed aHUS popPK model to individualize the predicted exposure for each patient with HSCT-TMA and to assess the impact of these factors from a patient population level. Standard assessments were used for model qualification.
  • Step 3 the qualified popPK model was used to perform simulations confirming/ adjusting the ravulizumab dose regimen, including transfusion-related supplemental doses. Monte Carlo simulation of concentration-time profiles was performed to assess if randomly generated exposures (based on population variability of PK parameters) would remain above the PK threshold, thus ensuring complete terminal complement inhibition.
  • FIG. 2 shows that the Day 5 and Day 10 loading doses appropriately managed high baseline levels of complement complexes, with ravulizumab concentrations maintained at >175 pg/mL.
  • the qualified popPK model characterized the dose-concentration relationship well. Further, it was determined that faster clearance occurred following RBC transfusions. Taking this into account, the simulations focused on adjusting/optimizing the transfusion-related supplemental dosing of ravulizumab.
  • the updated dose regimen is summarized in Table 1.
  • the Post-Transfusion Supplemental Dosing Schedule is set forth in Table 2.
  • a summary of the actions to take if one or more RBC transfusion occurs is set forth in Table 3.
  • Table 1 Updated Ravulizumab Weight-Based Dose Regimen a Weight-based dosing is based on the patient’s body weight recorded at the day of the infusion visit. If the weight at the day of the infusion cannot be obtained, the weight recorded during the previous study visit was used. bParti cipants with body weight >30 kg who received any red blood cell transfusion in the 4
  • a PK-PD analysis was conducted to confirm the ravulizumab dose regimen being used to treat patients with HSCT-TMA in a phase 3 study, substantially as described above in Example 1 and WO/2022/036151.
  • a supplemental dosing regimen was implemented in the present study for patients weighing less than 30 kg who received a platelet or RBC transfusion during treatment.
  • the Post-Transfusion Supplemental Dosing Schedule is set forth in Table 4.
  • Table 4 Post-Transfusion Supplemental Dosing Schedule for Patients Weighing Less Than 30 kg
  • Example 2 the dose regimen set forth in Table 4 was confirmed for 7/9 patients (22%). However, it was determined that certain patients weighing ⁇ 30 kg with frequent RBC transfusions (e.g., high ravulizumab clearance” patients weighing ⁇ 30 kg) may not maintain target trough level (175 mcg/mL) and therefore, not achieve complete C5 inhibition. Therefore, this particular group of patients could benefit further from a revised dose regimen. Accordingly, a revised dosing regimen as set forth in Table 5 is assessed in this patient group, substantially according to the methods described in Examples 1-2 and WO/2022/036151, with the noted modifications.
  • a post-RBC transfusion supplemental dose of ravulizumab is assessed when the patient reaches the mid-way point between maintenance doses as set forth in Table 6.
  • a post-RBC transfusion supplemental dose is administered if the participant has received at least 1 RBC transfusion since the last maintenance dose.
  • a clinical algorithm is followed to assess the need for post- RBC transfusion supplemental dosing Table 6: Timing of Post-RBC Transfusion Supplemental Dosing
  • the supplemental dose is administered within the same window for each weight categories. If supplemental dosing is required at the same time as a scheduled study visit, the dosing can take place at that visit.
  • the revised dosing regimen triggers a clinical algorithm when RBC transfusion day frequency exceeds >3.5 days /week (z.e.. the threshold for when >10% patients have trough level ⁇ 175 mcg/mL). Specifically, the clinical algorithm monitors the number of RBC transfusion days (the number of days with at least 1 RBC transfusion) and clinical worsening. Previously, the investigator assessed only whether the participant has received at least one RBC transfusion since the last maintenance dose. The revised dosing regimen is proposed to increase both maintenance and supplemental doses to mitigate issues.
  • the clinical algorithm is set forth in FIG. 3 and summarized in Table 7.
  • Supplemental doses of ravulizumab are allowed during the Treatment Period following administration of the first Maintenance Dose on Day 15 for patients who demonstrate clinical worsening.
  • Clinical worsening is defined as meeting 2 or more of the following criteria:
  • the minimum assessments to be performed during any supplemental dosing visit in which ravulizumab is administered include a urine pregnancy test, predose PK/PD blood sample collection, and vital signs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes de traitement de HSCT-TMA dans une sous-population de patients particulière (par exemple, des patients de HSCT-TMA ayant un poids corporel ≥ 30 kg qui ont reçu une transfusion (par exemple, une transfusion de plaquettes ou de globules rouges (RBC)) dans les 4 semaines suivant une dose d'entretien), comprenant l'administration au patient d'un anticorps anti-C5, ou d'un fragment de liaison à l'antigène de celui-ci, l'anticorps anti-C5 ou le fragment de liaison à l'antigène de celui-ci étant administré (ou étant destiné à être administré) selon un régime posologique clinique particulier (par exemple, à des quantités particulières de doses de charge, d'entretien et supplémentaires, et selon un programme particulier).
PCT/US2023/031836 2022-09-06 2023-09-01 Dosage supplémentaire et administration d'anticorps anti-c5 pour le traitement de la microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma) WO2024054408A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263404061P 2022-09-06 2022-09-06
US63/404,061 2022-09-06
US202363440984P 2023-01-25 2023-01-25
US63/440,984 2023-01-25

Publications (1)

Publication Number Publication Date
WO2024054408A1 true WO2024054408A1 (fr) 2024-03-14

Family

ID=88192212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/031836 WO2024054408A1 (fr) 2022-09-06 2023-09-01 Dosage supplémentaire et administration d'anticorps anti-c5 pour le traitement de la microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma)

Country Status (2)

Country Link
TW (1) TW202426048A (fr)
WO (1) WO2024054408A1 (fr)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088376B2 (en) 2004-11-12 2012-01-03 Xencor, Inc. Fc variants with altered binding to FcRn
US8241628B2 (en) 2008-08-05 2012-08-14 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
WO2015039126A1 (fr) * 2013-09-16 2015-03-19 Children hospital medical center Compositions et procédés pour le traitement de la microangiopathie thrombotique associée à la transplantation de cellules souches hématopoïétiques (tcsh)
US9079949B1 (en) 2014-03-07 2015-07-14 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
WO2016200627A1 (fr) * 2015-06-09 2016-12-15 Children's Hospital Medical Center Algorithme de dosage pour inhibiteur du complément
WO2017064615A1 (fr) * 2015-10-12 2017-04-20 Novartis Ag Utilisation d'inhibiteurs de c5 dans la microangiopathies associée à une greffe
US9765135B2 (en) 2014-12-19 2017-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies
US10633434B2 (en) 2016-06-14 2020-04-28 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies
WO2021058117A1 (fr) * 2019-09-27 2021-04-01 Volution Immuno Pharmaceuticals Sa Méthode de traitement de la microangiopathie thrombotique associée à une transplantation de cellules souches hématopoïétiques (hsct-tma)
WO2022036151A1 (fr) 2020-08-13 2022-02-17 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement de la microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma)
WO2022159373A1 (fr) * 2021-01-22 2022-07-28 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la microangiopathie thrombotique à médiation par le complément à l'aide d'un anticorps anti-c5

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088376B2 (en) 2004-11-12 2012-01-03 Xencor, Inc. Fc variants with altered binding to FcRn
US8241628B2 (en) 2008-08-05 2012-08-14 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
US8883158B2 (en) 2008-08-05 2014-11-11 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
WO2015039126A1 (fr) * 2013-09-16 2015-03-19 Children hospital medical center Compositions et procédés pour le traitement de la microangiopathie thrombotique associée à la transplantation de cellules souches hématopoïétiques (tcsh)
US9079949B1 (en) 2014-03-07 2015-07-14 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
WO2015134894A1 (fr) 2014-03-07 2015-09-11 Alexion Pharmaceuticals, Inc. Anticorps anti-c5 présentant une pharmacocinétique améliorée
US9765135B2 (en) 2014-12-19 2017-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies
WO2016200627A1 (fr) * 2015-06-09 2016-12-15 Children's Hospital Medical Center Algorithme de dosage pour inhibiteur du complément
WO2017064615A1 (fr) * 2015-10-12 2017-04-20 Novartis Ag Utilisation d'inhibiteurs de c5 dans la microangiopathies associée à une greffe
US10633434B2 (en) 2016-06-14 2020-04-28 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies
WO2021058117A1 (fr) * 2019-09-27 2021-04-01 Volution Immuno Pharmaceuticals Sa Méthode de traitement de la microangiopathie thrombotique associée à une transplantation de cellules souches hématopoïétiques (hsct-tma)
WO2022036151A1 (fr) 2020-08-13 2022-02-17 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement de la microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma)
WO2022159373A1 (fr) * 2021-01-22 2022-07-28 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la microangiopathie thrombotique à médiation par le complément à l'aide d'un anticorps anti-c5

Non-Patent Citations (44)

* Cited by examiner, † Cited by third party
Title
ANSEL ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT WILLIAMS & WILKINS
ARDISSINO GIANLUIGI ET AL: "Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy", PHARMACEUTICALS, vol. 15, no. 7, 9 July 2022 (2022-07-09), pages 845, XP093093478, DOI: 10.3390/ph15070845 *
CAS, no. 1803171-55-2
CC THOMAS: "Experimental Immunochemistry", 1961, SPRINGFIELD, pages: 135 - 240,135-139
CHO ET AL., BONE MARROW TRANSPLANT., vol. 41, no. 9, 2008, pages 813 - 820
CHO ET AL., TRANSPLANTATION., vol. 90, no. 8, 2010, pages 918 - 926
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 83
DALL'ACQUA, W. ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 23514 - 24
DATTA-MANNAN, A. ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 1709 - 17
DICK ET AL.: "Determination of the origin of the N-terminal pyro-glutamatevariation in monoclonal antibodies using model peptides", BIOTECHNOL. BIOENG., vol. 97, 2007, pages 544 - 553, XP002705607, DOI: 10.1002/bit.21260
DVORAK ET AL., FRONT PEDIATR., vol. 7, 2019, pages 133
EVANS, M. ET AL., MOL. IMMUNOL., vol. 32, 1995, pages 1183 - 95
FERRI FF: "Ferri's Clinical Advisor", 2014, ELSEVIER MOSBY
FUKUZAWA, T. ET AL., SCI. REP., vol. 7, 2017, pages 1080
HILL, A. ET AL., BR. J. HAEMATOL., vol. 149, 2010, pages 414 - 25
HILL, A. ET AL., HAEMATOLOGICA, vol. 93, no. 1, 2008, pages 359
HILLMEN, P. ET AL., N. ENGL. J. MED., vol. 350, 2004, pages 552 - 9
HINTON, P. ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 6213 - 6
HINTON, P. ET AL., J. IMMUNOL., vol. 176, 2006, pages 346 - 56
HUSE, W. ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 81
JODELE ET AL., BLOOD REV., vol. 29, no. 3, 2015, pages 191 - 204
JODELE ET AL., BLOOD., vol. 124, no. 4, 2014, pages 645 - 653
JOHNE, B. ET AL., J. IMMUNOL. METH., vol. 160, 1993, pages 191 - 8
JONSSON, U. ET AL., ANN. BIOL. CLIN., vol. 51, 1993, pages 19 - 26
JONSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 7
KANAKURA, Y. ET AL., INT. J. HEMATOL., vol. 93, 2011, pages 36 - 46
KATO, G. ET AL., BLOOD, vol. 107, 2006, pages 2279 - 85
KHOSLA ET AL., BONE MARROW TRANSPLANT., vol. 53, no. 2, 2018, pages 129 - 137
KIBBE: "Handbook of Pharmaceutical Excipients American Pharmaceutical Association", 2000, LIPPINCOTT, WILLIAMS & WILKINS
KOHLER, G.MILSTEIN, C., EUR. J. IMMUNOL., vol. 6, 1976, pages 511 - 9
LIU ET AL., J PHARM SCI ., vol. 108, no. 10, October 2019 (2019-10-01), pages 3194 - 3200, Retrieved from the Internet <URL:https://pubmed.ncbi.nlm.nih.gov/31145921>
MASIAS ET AL., BLOOD., vol. 129, no. 21, 2017, pages 2857 - 2863
NGUYEN ET AL., INT. J. MOL. SCI., vol. 18, no. 7, 20 July 2017 (2017-07-20), pages 1575, Retrieved from the Internet <URL:https://www.researchgate.net/figure/Cyclization-reactions-of-N-terminal-glutamine-and-glutamate-residues-in-a-polypeptide_fig4_318926365>
PARKER, C. ET AL., BLOOD, vol. 106, 2005, pages 3699 - 709
PETKOVA, S. ET AL., INT. IMMUNOL., vol. 18, 2006, pages 1759 - 69
ROSENTHAL ET AL., J. BLOOD MED., vol. 7, 2016, pages 181 - 186
ROSENTHAL ET AL., J. BLOODMED., vol. 7, 2016, pages 181 - 186
SEABY ET AL., PEDIATR NEPHROL., vol. 33, no. 9, 2018, pages 1489 - 1500
SEABY ET AL., PEDIATR. NEPHROL., vol. 33, no. 9, 2018, pages 1489 - 1500
THOMAS, C. ET AL., MOL. IMMUNOL., vol. 33, 1996, pages 1389 - 401
VAN LENTE, F. ET AL., CLIN. CHEM., vol. 27, 1981, pages 1453 - 5
WANCHOO ET AL., AM. J. KIDNEY DIS., vol. 72, no. 6, 2018, pages 857 - 865
XU ET AL., MABS, vol. 11, no. 2, February 2019 (2019-02-01), pages 239 - 264
YU ET AL.: "Investigation of N-terminal glutamatecyclization of recombinant monoclonal antibody in formulation development", J. PHARM. BIOMED. ANAL., vol. 42, 2006, pages 455 - 463

Also Published As

Publication number Publication date
TW202426048A (zh) 2024-07-01

Similar Documents

Publication Publication Date Title
US20210332147A1 (en) DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) IN PEDIATRIC PATIENTS
JP7520725B2 (ja) 小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与
US20210395352A1 (en) Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
KR20210119420A (ko) 비정형 용혈성 요독증후군(ahus)의 치료를 위한 항-c5 항체의 복용량 및 투여
JP2024504366A (ja) 抗ｃ５抗体を使用して補体媒介血栓性微小血管障害症を治療する方法
AU2021326526A1 (en) Dosage and administration of anti-C5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)
WO2024054408A1 (fr) Dosage supplémentaire et administration d&#39;anticorps anti-c5 pour le traitement de la microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma)
JP2024503724A (ja) 免疫調節抗体およびその使用
JP7577542B2 (ja) 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
US20230172930A1 (en) Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
JP2023533030A (ja) 小児患者において発作性夜間血色素尿症（ｐｎｈ）を治療するための抗ｃ５抗体の投薬量及び投与
JP2023507852A (ja) 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
TW202423479A (zh) 用於預防或最小化患有慢性腎病的患者中的心臟手術相關急性腎損傷（csa-aki）和/或隨後的主要不良腎事件（make）的抗c5抗體之劑量及投與
JP2024521474A (ja) 皮膚筋炎（ｄｍ）を治療するための抗ｃ５抗体の投与量及び投与
AU2021361067A1 (en) Compositions and methods for treating blood disorders
WO2023107100A1 (fr) Procédés et traitement pour le myélome multiple mettant en œuvre des anticorps dirigés contre il-18
CN118103064A (zh) 用补体旁路途径抑制剂治疗镰状细胞病或β地中海贫血的方法
JP2023547505A (ja) ＳＡＲＳ－ＣｏＶ－２ヌクレオカプシド抗体
EP4213940A1 (fr) Dosage et administration d&#39;anticorps anti-c5 pour le traitement de la néphrite glomérulaire à médiation par c5 (gn), y compris la néphrite lupique (ln) et/ou la néphropathie à l&#39;iga (igan)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23776777

Country of ref document: EP

Kind code of ref document: A1